The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Treatment of hepatitis C virus infection with direct-acting antiviral drugs is safe and effective in patients with hemoglobinopathies
Origa R1, Ponti ML2, Filosa A3, Galeota Lanza A3, Piga A4, Saracco GM4, Pinto V5, Picciotto A6, Rigano P7, Madonia S7, Rosso R8, D'Ascola D9, Cappellini MD10, D'Ambrosio R10, Tartaglione I11, De Franceschi L12, Gianesin B5, Di Marco V13, Forni GL5; Italy for THAlassemia and hepatitis C Advance - Società Italiana Talassemie ed Emoglobinopatie (ITHACA-SITE). Am J Hematol. 2017 Sep 20. doi: 10.1002/ajh.24911. [Epub ahead of print]
Author information
1
University of Cagliari, Ospedale Pediatrico Microcitemico "A. Cao", Cagliari, Italy.
2
Medicina 1, AO Brotzu, Cagliari, Italy.
3
Cardarelli Hospital, Naples, Italy.
4
University of Turin, Turin, Italy.
5
Centro della Microcitemia e delle Anemie Congenite, Galliera Hospital, Genoa, Italy.
6
DIMI, University of Genoa, Genoa, Italy.
7
Villa Sofia-Cervello Hospital, Palermo, Italy.
8
Ferrarotto Hospital, Policlinico Vittorio Emanuele, Catania, Italy.
9
Centro Microcitemia, Reggio Calabria, Italy.
10
University of Milan, Ca Granda Foundation IRCCS, Milan, Italy.
11
University of Campania "Luigi Vanvitelli", Naples, Italy.
12
University of Verona, Verona, Italy.
13
University of Palermo, Italy.
Abstract
Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon-free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct-acting antiviral drugs (DAAs) in this patient population are few. This observational study evaluated the safety and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chronic HCV infection and advanced liver fibrosis. Between March 2015 and December 2016, 139 patients received DAAs and completed 12 weeks of follow up after the end of treatment for the evaluation of sustained virological response (12SVR). The 12SVR (93.5%) was comparable with that typically observed in cirrhotic patients without hemoglobinopathies. Three patients died during the period of observation of causes unrelated to DAAs. One patient did not achieve a virological response and five (3.6%) relapsed during 12 weeks of follow-up after the end of therapy. In addition, patients showed significant reductions in serum ferritin at 12 weeks to levels similar to those observed in a control group of 39 patients with thalassemia major without HCV infection, who adhered to chelation therapy and had no overt iron overload. In conclusion, the use of DAAs appears to be safe and effective in patients with hemoglobinopathies and advanced liver disease due to HCV.